Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASP II TR: Edwards PASCAL System in Tricuspid Regurgitation
NCT04097145Recruiting
- Sponsor
- Edwards Lifesciences
- Start
- Dec 2019
- Primary completion
- Dec 2027
- Countries
- 2
01
Overview
Randomised, open-label trial in tricuspid regurgitation (4 arms), sponsored by Edwards Lifesciences. Primary endpoint: Composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention, heart failure hospitalizations, and Quality of Life improvement at 6 months. Started Dec 2019; status: recruiting.
02
Conditions
tricuspid regurgitation
Beyond the preview
Go deeper on NCT04097145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097145.